Re Mesoblast and govt aid. Problem we have is that the IP resides with QUT whilst TIS bears the risk. All our R&D expendidture over the past 10 yrs has passed thru QUT and govt grants have been paid to them. This IP anomaly must be resolved or we have no future - except years of lawyers picking over the carcase.
Assuming we can transfer the VitroGro IP to TIS then we look the part and could be well positioned for govt assistance. I was interested in the formation of the Brandon Capital venture capital fund for commercialisation of Australian medical research. We may well have a product that meets their requirements.
